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Background: Cost-effectiveness studies explicitly reporting infusion times, drug-specific administration costs for
infusions or real-payer intravenous drug cost are few in number. Yet, administration costs for infusions are needed
in the health economic evaluations assessing intravenously-administered drugs.
Objectives: To estimate the drug-specific administration and total cost of biologic intravenous rheumatoid arthritis
(RA) drugs in the adult population and to compare the obtained costs with published cost estimates.
Methods: Cost price data for the infusions and drugs were systematically collected from the 2011 Finnish price
lists. All Finnish hospitals with available price lists were included. Drug administration and total costs (administration
cost + drug price) per infusion were analysed separately from the public health care payer’s perspective. Further
adjustments for drug brand, dose, and hospital type were done using regression methods in order to improve the
comparability between drugs. Annual expected drug administration and total costs were estimated. A literature
search not limited to RA was performed to obtain the per infusion administration cost estimates used in
publications. The published costs were converted to Finnish values using base-year purchasing power parities and
indexing to the year 2011.
Results: Information from 19 (95%) health districts was obtained (107 analysable prices out of 176 observations).
The average drug administration cost for infliximab, rituximab, abatacept, and tocilizumab infusion in RA were
€355.91; €561.21; €334.00; and €293.96, respectively. The regression-adjusted (dose, hospital type; using semi-log
ordinary least squares) mean administration costs for infliximab and rituximab infusions in RA were €289.12
(95% CI €222.61–375.48) and €542.28 (95% CI €307.23–957.09). The respective expected annual drug administration
costs were €2312.96 for infliximab during the first year, €1879.28 for infliximab during the forthcoming years,
and €1843.75 for rituximab. The obtained average administration costs per infusion were higher (1.8–3.3 times
depending on the drug) than the previously published purchasing power adjusted and indexed average
administration costs for infusions in RA.
Conclusions: The administration costs of RA infusions vary between drugs, and more effort should be made to find
realistic drug-specific estimates for cost-effectiveness evaluations. The frequent assumption of intravenous drug
administration costs equalling outpatient visit cost can underestimate the costs.
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Finland has a decentralized and mostly taxation-funded
public health care system (e.g. Teperi et al. 2009; OECD
2005; Häkkinen 2005; Hermanson et al. 1994). The
responsibility of health care organization resides with
municipalities which are required by law to belong to
consortiums (i.e. joint municipal boards) that organize
specialized health care services for their residents. Con-
sortiums govern health care districts (20 mainland main
districts in total; Åland Islands excluded) that are funded
by the municipalities that belong to the consortium.
Essentially, the patients’ home municipalities pay the
intravenous (IV) drug administration and drug costs in
this system. Because the health care districts are
regarded as non-profit organizations and the invoicing
of municipalities is based on cost prices (“absorption
costing”), the price lists of health care district hospitals
can be used to estimate the infusion costs for the
Finnish public payer.
The publications explicitly reporting infusion times,
drug-specific administration costs for infusions or real-
payer IV drug cost are few in number. Yet, administra-
tion costs are needed in the health economic evaluations
assessing intravenously-administered drugs. In this study
the primary objective was to estimate the pooled and
drug- and dose-stratified average as well as adjusted
mean administration costs of biologic IV drugs that are
given as infusions at Finnish hospitals to treat rheuma-
toid arthritis (RA) in adults. The obtained estimates are
compared with the purchasing power adjusted costs
used in published health economic assessments.
Methods
The biologic IV drugs included in the analysis were
infliximab (IFX), rituximab (RTX), abatacept (ABA) and
tocilizumab (TCZ). ABA (750 mg for patient weighting
60–100 kg) and TCZ (8 mg/kg) are indicated for RA,
IFX is indicated for RA (3 mg/kg), Crohn’s disease
(5 mg/kg) and psoriasis (3–5 mg/kg), and RTX is indi-
cated for RA (500–1000 mg), chronic lymphocytic leu-
kaemia (375–500 mg/m2) and non-Hodgkin’s (follicular)
lymphoma (375 mg/m2). Based on the summaries of
product characteristics and Finnish RA practice, IFX is
given as 2–3 hour, RTX is given as 3.5–5 hour, TCZ is
given as a 1.0–1.5 hour and ABA is given as a thirty mi-
nute infusion (e.g. Soini et al. 2012a).
Data collection
A systematic collection of the price lists of Finnish
health care districts and public and private hospitals was
performed. The health care districts invoice the munici-
palities on the basis of these price lists and as such the
reported prices represent the ‘true’ cost for the public
payer. At first, cost price lists for 2011 were sought fromthe service providers’ internet pages. If the price list was
not published, a standardized e-mail enquiry was sent to
the service providers (two reminders were sent). All pos-
sible hospitals (i.e. university, central district, district and
private hospitals) potentially giving biologic drug infu-
sions for RA were included to the enquiry.
The IV treatment cost prices for RA were gathered from
the price lists through a keyword search of electric files
and manual inspection if no matches were obtained with
the keyword search. The following key words were used:
drug brand names (Remicade, Mabthera, Rituxan, Orencia,
RoActemra, Actemra), the name of the active substance in
Finnish (infliksimabi, rituksimabi, abatasepti, tosilitsumabi)
or in English (infliximab, rituximab, abatacept, tocilizu
mab). In the manual inspection, all observations which
could be clearly interpreted as a particular IV drug were in-
cluded (including “expensive / biologic drug infusions to
treat RA”). The following data were extracted: service pro-
vider, hospital type, medical speciality, procedure code,
drug name, dosing, infusion list cost price, items included
in the list cost price (drug alone, administration alone or
both drug and administration) and source.
The final data set was obtained by excluding observa-
tions that did not match the study objective. The
infusions given by clearly unrelated medical specialities
(paediatrics, neurologic, haematology, lung diseases,
gynaecology, ear, nose and throat diseases, oncology,
surgery and skin diseases) were excluded because of the
dosing variation in different diseases and/or because
these list cost prices included other drugs outside the
scope of this analysis.
In the cases, when it was impossible to separate the
drugs or no specific price for particular drug was given,
“expensive RA drugs” class was used for them. Expensive
RA drugs class include a variety of RA drugs which were
not specified in sufficient details in the price lists, and
mostly infliximab, abatacept and rituximab infusions
were involved. This class was included to have all the
possible cost data available for the regression models.
Cost classification
The following cost categories were analysed separately
based on the list cost prices
1. The administration costs (the main outcome of
the analysis) per infusion: as reported in the price
list, or alternatively the dose-dependent wholesale
price of the drug was subtracted from the total
costs, if the drug administration price was not
reported separately from the drug price. The
subtraction was performed only when the drug
name and the dose information were presented,
and was therefore not done for the expensive RA
drugs class.
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The obtained list prices were also classified into RA-
indicated adult doses (based on summaries of product
characteristics and, if needed, assumed weight of 73 kg
(Paturi et al. 2008; Soini et al. 2012a)) and atypical doses
(higher or lower). The RA-indicated doses for adults in
this analysis were 3 mg/kg for IFX, 500–1000 mg for
RTX, 750 mg for ABA and 8 mg/kg for TCZ. A further
subgroup included a pool of biologic antirheumatic
drugs (bDMARD) with or without dosing information
and for which the drug brands were not explicitly stated
in the price lists.
Statistical analysis
Unadjusted pooled averages and average values stratified
for drug doses and drug brands were estimated for
administration and total costs. The cost differences
between the intravenous biologics were assessed with a
non-parametric test (Wilcoxon signed rank test) due
to a modest number of observations in subgroups
(p-value below 0.05 was considered to indicate statistical
significance).
Regression analyses were performed to obtain adjusted
drug administration and total cost estimates and to allow
multivariate statistical comparisons between the drugs.
The costs were adjusted for drug doses (dummies for
low and high doses), drug brands (dummies for ABA,
TCZ and RTX) and hospital type (dummies for univer-
sity hospital and regional hospital); the contrast was IFX
with RA-indicated dose in central hospital. Regression
analyses were performed using ordinary least squares
(OLS), OLS with logarithmic (ln) conversion for the cost
variable using Duan’s (Duan 1983) smearing (LN-OLS)
and generalized linear modelling (GLM) (see e.g. Hallinen
et al. 2006; Soini et al. 2012b) with the fittest distribution
and link function. Akaike information criteria (AIC),
Bayesian information criteria (BIC), log likelihood (LL)
and coefficient of determination (R2) were reported.
The best regression model for heterogeneity adjust-
ment between drug brands (“significant” model) was
determined using a procedure based on AIC and R2:
the least significant coefficients were excluded from the
model until AIC did not improve anymore and R2 did
not drop. The best model type (OLS, LN-OLS or GLM)
among adjustment models was determined using AIC
and BIC. Analyses were implemented in Stata v10.
Administration costs in previous publications
A rapid review was done of the existing publications
(15th August 2011) from the PubMed and Cochrane da-
tabases, and from potential Finnish medical, pharmacist
and social science scientific journals in order to find outthe published administration costs for IV biologics (IFX,
RTX, ABA, TCZ) in various diseases and to reflect the
RA administration costs of this study. The search terms
included (in English and Finnish): cost, price, pricing,
resource, resourcing, budget, economic OR burden
AND Remicade, Rituxan, Mabthera, Orencia, Actemra,
RoActemra, infliximab, rituximab, abatacept, atlizumab
OR tocilizumab. Total costs were not searched, because
the drug prices during the base year in the given country
were unknown, and the pricing as well as reimburse-
ment (payment system) of the drug costs may differ sig-
nificantly due to local setups (see e.g. Hallinen and Soini
2011). Publications were included in the review if the
used currency, the base costing year, the drug brand and
the given drug administration cost were clearly stated.
In order to obtain comparability with the Finnish cost
prices for 2011 and average costs estimated in the main
analysis, the costs obtained from the literature review
were converted to their base year Finnish costs using
purchasing power parities (PPP) obtained from OECD
and were presented in 2011 values using the official
Finnish health care price index obtained from Statistics
Finland.
Results
The cost price data for 2011 from 19 (95%) health dis-
tricts were obtained for the raw data. No private hospi-
tals sent their price data and two private hospitals stated
that they do not administer these infusions. As a result,
the costs presented here capture the public health care
payer’s perspective. The obtained sources of the cost
price data are presented in the Appendix 1.
The raw data consisted of 176 list cost prices in total.
After exclusion of irrelevant cost prices (i.e. list prices not
matching the study objective), 107 cost prices (60.8% of
raw data) remained for inclusion in the analysis. The cost
prices from RA departments (four prices, 3.7%), internal
disease departments treating RA (63 prices, 58.9%) and of
expensive RA drugs (forty prices, 37.4%) were included.
The costs of biologic RA drug infusions varied between
different Finnish public service providers.
Pooled costs
For crude administration cost analysis and total costs
analysis, 82 (76.6%) and 106 valid list prices (99.1%),
respectively, were included in the sample. The pooled
(i.e. all drug brands and doses combined) crude average
administration costs were €404.06 (S.D. €269.04, n=82)
and total costs were €2826.28 (S.D. €1601.23, n=106) per
infusion.
The pooled average administration costs for doses in-
dicated for adult RA were €400.36 (S.D. €259.61, n=63)
and total costs were €2831.72 (S.D. €1690.41, n=63).
The pooled average administration costs and total costs
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€827.15, n=23), respectively, for doses deviating from
adult RA indication. For twenty list prices (total costs
average €2955.35, S.D. €2031.26) the dosing was not
stated. There were no statistically significant differences
between the costs matching the adult RA indication and
undefined doses or doses outside the indicated doses.
The summary statistics according to drug brand re-
gardless of used doses are represented in Table 1. The
average administration costs were highest for RTX and
lowest for IFX, while the average total costs were highest
for IFX and lowest for ABA. The difference between ad-
ministration costs as well as total costs of the most and
least expensive drug were statistically significant (p<0.01
for both cost types in all analyses).
The average costs stratified by dose and drug brand
The stratified results by drug using the indicated adult
RA dose or other dose are represented in Table 2. The
average administration cost with the indicated adult RA
dose was €355.91 for IFX, €561.21 for RTX, €334.00 for
ABA and €293.96 for TCZ. The average total costs for
adult RA doses were €2243.10 for IFX, €3619.17 for
RTX, €1450.00 for ABA and €2176.00 for TCZ. RTX
500–1000 mg administration was not significantly
more costly compared with IFX 3 mg/kg administration
whereas RTX 500–1000 mg total costs were significantly
higher compared with IFX 3 mg/kg total costs (p<0.01).
The variability in costs was reduced significantly,
when the commonly indicated and non-indicated RA
drug-specific doses were taken into account. The cost
variability was lower with the indicated RA dose when
compared to the variability of costs based on the non-
indicated dose. The average administration costs per
infusion with the non-indicated adult RA doses were
lowest for IFX and highest for RTX. The average total
costs per infusion with the non-indicated adult RA doses
were lowest for TCZ and highest for IFX. IFX and RTX
with the indicated adult RA dose were not significantly
different from their non-indicated adult RA doseTable 1 Total and administration costs (€2011) of public heal
Drug Administration (€, N 82) per
N Average S.D.
Infliximab 52 330.87b 158.27
Rituximab 20 578.38b 425.65
Abatacept 5 455.60 138.22
Tocilizumab 5 414.63 202.00
Expensive infusion with RA dose 0 NR NR
Other expensive infusion 0 NR NR
RA = rheumatoid arthritis. N = number of observations. S.D. = standard deviation. N
administration cost was statistically significantly different from average RTX adminis
significantly different from average RTX total cost (p-value = 0.175).whereas IFX and RTX with the indicated adult RA dose
were significantly less costly compared with their non-
indicated adult RA dose (p<0.05 for both in all analyses).
Adjusted mean costs
The models used for drug administration and total cost
adjustments (drug brand, dose, hospital type) and multi-
variate comparisons are represented in Tables 3 and 4,
respectively. Dosing was separated for low, RA and high
drug doses in the regression models. Robust estimation
was used in all models.
Based on the best-fitting model (LN-OLS, semi-log
OLS, logarithmic distribution assumption for adminis-
tration costs; Table 3), the adjusted administration mean
costs with the indicated RA dose were €289.12 (95% CI
€222.61–375.48) for IFX and €542.28 (95% CI €307.23–
957.09) for RTX per infusion in a central hospital. ABA
and TCZ administration costs as well as regional hos-
pital administrations were based on a few relatively high
cost estimates and were, thus, potentially biased upwards
in the regressions. The adjusted administration costs for
higher doses were significantly more costly (p<0.01) in
comparison with the administration of indicated adult
RA doses, whereas there was no statistically significant
difference between the adjusted administration costs for
lower doses and indicated adult RA doses.
Based on the best-fitting LN-OLS model, the adjusted
total mean costs (Table 4) with the indicated RA dose
were €2540.97 (95% CI €2329.48–2771.93) for IFX and
€3367.08 (95% CI €2669.11–4247.99) for RTX per infu-
sion. ABA and TCZ total costs were based on only a few
cost estimates and may not be representative. RTX total
costs were significantly higher (p<0.05) in comparison
with IFX, when adjusted for drug, dose and hospital
type. The total costs of TCZ, ABA or pool of bDMARDs
did not differ statistically significantly from the total
costs of IFX, when adjusted for dose and hospital type.
High doses were significantly more costly and low doses
significantly less costly in comparison with the indicated
adult RA doses (p<0.001 for both).th care payer by drug regardless of dosing
infusion Total costsa (€, N 106) per infusion
Range N Average S.D. Range
25–728 51 3128.21c 1560.96 647-6648
15–1572 20 2612.37c 1412.06 342-6147
334–688 5 1422.80 440.05 1120-2176
263–728 5 1454.00 416.33 1204-2176
NR 5 2873.20 1056.19 1695-3895
NR 20 2955.35 2031.26 1390-10213
R = not reported. a Includes administration and drug costs. b Average IFX
tration cost (p-value = 0.007). c Average IFX total cost was not statistically
Table 2 Administration and total costs (€2011) by the indicated common and non-indicated adult RA dose
Drug
RA dose
Administration (€, N 82) per infusion Total costsa (€, N 106) per infusion
N Average S.D. Range N Average S.D. Range
Infliximab Yes 11bc 355.91 125.45 123–543 10ef 2243.10 110.92 1990–2410
No 41b 324.15 166.69 25–728 41e 3344.09 1673.13 647–6648
Rituximab Yes 6cd 561.21 516.78 142–1572 6fg 3619.17 516.78 3200–4630
No 14d 586.37 402.34 15–1560 14g 2180.88 1463.94 342–6147
Abatacept Yes 1 334.00 NS NS 1 1450.00 NS NS
No 4 486.00 138.97 376–688 4 1416.00 507.83 1120–2176
Tocilizumab Yes 1 293.96 NS NS 1 2176.00 NS NS
No 4 444.80 219.86 263–728 4 1273.50 117.91 1204–1450
RA = rheumatoid arthritis. N = number of observations. S.D. = standard deviation. NS = not stated. a Includes administration and drug costs. b IFX using RA dose
did not have significantly lower administration costs compared with IFX not using RA dose. c RTX with RA dose was not significantly more costly compared with
IFX with RA dose. d RTX using RA dose did not have significantly lower administration costs compared with RTX patients using RA dose. e IFX patients using RA
dose had significantly lower total costs compared with IFX patients not using RA dose (p-value = 0.013). f RTX patients using RA dose had significantly lower
total costs compared with RTX patients not using RA dose (p-value = 0.011). g RTX with RA dose was significantly more costly compared with IFX with RA dose
(p-value = 0.001).
Table 3 Statistical models for adjusted per-infusion administration costs (€2011)
Parametera OLS (full) OLS (sign.) LN-OLS (full) LN-OLS (sign.) GLM (full)b GLM (sign.)b
Coef. 95% CI Coef. 95% CI Coef. 95% CI Coef. 95% CI Coef. 95% CI Coef. 95% CI
University hospital −133.07 −139.23* −0.5129 −0.6008* −134.57** −172.52***
−272.85–6.71 −252.98–-25.49 −1.1299–0.1041 −1.1449–-0.0567 −232.93–-36.21 −245.95–-99.09
District hospitalc 10.29 NR 0.1467 NR 63.02 NR
−130.59–151.17 −0.2432–0.5366 −57.96–184.01
Rituximab 332.89** 332.33** 0.6370* 0.6290* 327.67*** 318.99***
94.04–571.73 96.44–568.21 0.0591–1.2148 0.0608–1.1971 151.78–503.57 144.90–493.08
Abataceptd 191.62* 186.47** 0.7960* 0.7225* 262.52*** 245.90***
34.78–348.47 47.20–325.75 0.1767–1.4152 0.1431–1.3019 171.59–353.45 150.93–340.87
Tocilizumabd 195.76 192.98 0.7995* 0.7598* 233.88*** 230.25***
−57.66–449.19 −51.25–437.20 0.0938–1.5051 0.0438–1.4758 116.70–351.07 102.52–357.99
Low dose −88.12 −86.51 −0.4786 −0.4556 −153.19*** −146.56***
−255.55–79.30 −251.47–78.45 −0.9849–0.0277 −0.9427–0.0314 −228.44–-77.94 −221.47–-71.66
High dose 147.71* 150.86* 0.4219* 0.4669** 101.20* 110.66**
8.72–286.69 9.02–292.70 0.1041–0.7396 0.1804–0.7534 20.06–182.34 31.94–189.38
Constant 313.92*** 318.71*** 5.5986*** 5.6668*** 330.90*** 363.50***
196.40–431.44 230.55–406.86 5.2776–5.9197 5.4054–5.9282 243.30–418.50 293.01–433.99
Tests
N 82 82 82 82 82 82
R2 0.29 0.29 0.29 0.28 NR NR
Prob 0.015* 0.008** 0.002** 0.002** NR NR
LL −560.38 −560.39 −86.94 −87.23 −567.96 −568.19
AIC 1136.75 1134.78 189.87 188.46 1151.92 1150.38
BIC 1156.00 1151.63 209.12 205.30 1171.18 1167.23
OLS = ordinary least squares regression model. Sign. = significant model. LN-OLS = OLS regression model with logarithmic transformation in dependent
parameter. GLM = generalized linear model regression. Coef. = coefficient. 95%CI = 95% confidence interval. * p-value < 0.050. ** p-value < 0.010. *** p-value < 0.001.
NR = not reported. N = number of observations. R2 = coefficient of determination. Prob = model p-value. LL = log likelihood. AIC = Akaike information criteria.
BIC = Bayesian information criteria. a Contrast is central district hospital, infliximab and indicated common adult rheumatoid arthritis dose. b Gamma distribution and
linear link function in GLM provided the best fit among GLMs. c Few costs were obtained from (non-university or non-central) district hospitals.
d Potentially biased upwards due to low number of observations.
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Table 4 Statistical models for adjusted per-infusion total (administration and drug) costs (€2011)
Parametera OLS (full) OLS (sign.) LN-OLS (full) LN-OLS (sign.) GLM (full)b GLM (sign.)b
Coef. 95% CI Coef. 95% CI Coef. 95% CI Coef. 95% CI Coef. 95% CI Coef. 95% CI
University hospital 5.35 NR 0.0243 NR 0.0100 NR
−537.73–548.42 −0.2525–0.3011 −0.1683–0.1882
District hospitalc 155.44 NR 0.1171 NR 0.0614 NR
−277.97–588.84 −0.0767–0.3109 −0.0774–0.2003
Rituximab 807.61*** 773.22*** 0.2943* 0.2815* 0.3502*** 0.3340***
434.58–1180.64 398.34–1148.10 0.0545–0.5339 0.0492–0.5139 0.1974–0.5030 0.1834–0.4847
Abataceptd −619.85 −713.33 −0.1826 −0.2440 −0.2158 −0.2553
−1836.24–596.54 −1920.71–494.05 −0.6012–0.2360 −0.6516–0.1635 −0.5026–0.0710 −0.5337–0.0231
Tocilizumabd 70.29 9.43 0.0897 0.0548 0.0248 −0.0034
−332.87–473.44 −395.93–414.79 −0.1444–0.3238 −0.1630–0.2715 −0.1447–0.1942 −0.1622–0.1553
Pool of bDMARDs 359.77 NR 0.1167 NR 0.1603 NR
−747.32–1466.86 −0.2955–0.5290 −0.1443–0.4650
Low dose −1449.67*** −1477.90*** −0.7999*** −0.8005*** −0.7217*** −0.7325***
−1776.25–-1123.09 −1799.91–-1155.89 −1.0147–-0.5852 −1.0041–-0.5968 −0.8763–-0.5671 −0.8823–-0.5828
High dose 2000.45*** 1979.89*** 0.5459*** 0.5586*** 0.5873*** 0.5762***
1415.46–2585.45 1453.46–2506.33 0.3814–0.7104 0.4225–0.6947 0.4546–0.7200 0.4546–0.6979
Constant 2511.29*** 2626.89*** 7.7763*** 7.8403*** 7.7980*** 7.8491***
2232.45–2790.13 2416.33–2837.45 7.6524–7.9000 7.7534–7.9273 7.7070–7.8891 7.7716–7.9266
Tests
N 86 86 86 86 86 86
R2 0.76 0.76 0.71 0.71 NR NR
Prob 0.00*** 0.00*** 0.00*** 0.00*** NR NR
LL −688.32 −689.07 −25.83 −26.91 −758.35 −758.42
AIC 1394.65 1390.14 69.66 65.81 1534.70 1528.84
BIC 1416.74 1404.86 91.75 80.54 1556.78 1543.56
OLS = ordinary least squares regression model. Sign. = significant model. LN-OLS = OLS regression model with logarithmic transformation in dependent
parameter. GLM = generalized linear model regression. Coef. = coefficient. 95%CI = 95% confidence interval. * p-value < 0.050. ** p-value < 0.010. *** p-value < 0.001.
NR = not reported. bDMARD = biologic antirheumatic drug. N = number of observations. R2 = coefficient of determination. Prob = model p-value. LL = log likelihood.
AIC = Akaike information criteria. BIC = Bayesian information criteria. a Contrast is central district hospital, infliximab and indicated common adult rheumatoid arthritis
dose. b Gamma distribution and log link function in GLM provided the best fit among GLMs. c Few costs were obtained from (non-university or non-central) district
hospitals. d Can be biased upwards due to low number of observations.
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maries of product characteristics for the annual number of
infusions, the public payer average annual administration /
total costs directly related to the respective biologic RA
drug infusions are estimated to be €2312.96 / €20,327.76
for IFX during the first year (eight infusions), €1879.28 /
€16,516.31 for IFX during the forthcoming years (6.5 infu-
sions) and €1843.75 / €11,448.07 for RTX (2×1.7 infusions
Soini et al. 2012a), per year.
Reference: published costs
In the review of published literature, 56 articles repor-
ting 76 costs were found for further review. Valid cost
data for infusion administration was reported in 20
articles (Beresniak et al. 2011; Bodger et al. 2009;
Chen et al. 2006; Cummins et al. 2011; Dretzke et al.2011; Fonia et al. 2010; Hallinen et al. 2010; Jobanputra
et al. 2002; Kasteng et al. 2008; Lekander et al. 2010;
Lindsay et al. 2008; Lyseng-Williamson and Foster 2004;
Malottki et al. 2011; Punekar et al. 2010; Rodgers et al.
2011; Soini et al. 2011; Tsai et al. 2008; Vera-Llonch
et al. 2008a, b; Woolacott et al. 2006; Yuan et al. 2010)
with 28 costs. In many published cost-effectiveness eval-
uations, the IV drug administration cost was based on
assumption (e.g. cost equalling outpatient or nurse visit).
In the literature review of the existing publications in-
cluding IFX, RTX, ABA or TCZ and administration
costs, the pooled average administration cost regardless
of drug, dose and disease was €199.60 (range €76.87–
484.57, S.D. €94.92, n=28). The average administration
cost was €158.75 (range €76.87–212.79, S.D. €45.44,
n=6) with ABA, €169.67 (range 76.87–230.97, S.D.
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484.57, S.D. €109.62, n=16) with IFX (disease and dose
ignored). The average administration cost was €163.08
(n=1) with ulcerative colitis, €176.35 (range €76.87–
270.23, S.D. €54.30, n=17) with RA, €165.02 (range
€99.06–230.97, S.D. €65.96, n=2) with non-Hodgkin’s
(follicular) lymphoma, €247.88 (range €108.02–484.57,
S.D. 141.98, n=4) with psoriatic arthritis and psoriasis,
and €276.58 (range €163.08–484.57, S.D. €129.31, n=4)
with Crohn’s disease (drug ignored).
The average administration costs stratified by drug
and disease obtained from the published literature are
presented in Table 5. The lowest (€158.75) RA average
administration cost was with ABA and the highest
(€193.92) with IFX. The costs assumed in the publica-
tions were generally lower than the estimates based on
our sample (1.8–3.3 times lower depending on the drug
and in comparison with the stratified average costs).
Discussion
The administration and total costs of biologic drug infu-
sions for RA vary between different Finnish public ser-
vice providers based on the cost price information for
2011. Based on the drug and dose stratified analysis, the
average infusion administration / total costs with the
common indicated RA adult doses were €355.91 /
€2243.10 for IFX, €561.21 / €3619.17 for RTX, €334.00 /
€1450.00 for ABA and €293.96 / €2176.00 for TCZ, re-
spectively, per infusion.
The dose and hospital type adjusted administration /
total mean costs with RA dose were €289.12 / €2540.97
for IFX and €542.28 / €3367.08 for RTX based on the
best-fitting significant (LN-OLS) model, respectively, per
infusion. The respective annual administration / total
costs were estimated to be €2312.96 / €20,327.76 for IFX
during the first year, €1879.28 / €16,516.31 for IFX dur-
ing the forthcoming years, and €1843.75 / €11,448.07 for
RTX, per year. The rank order of the drugs in terms of
their cost remained in the different adjustments made
and showed the robustness of findings. Due to the few
ABA and TCZ costs found, reliable adjusted means forTable 5 Results of the literature review: the average administ
Druga Disease N
IFX Rheumatoid arthritis 7
RTX Rheumatoid arthritis 4
ABA Rheumatoid arthritis 6
IFX Crohn’s disease 4
IFX Psoriatic arthritis, psoriasis 4
IFX Ulcerative colitis 1
RTX Follicular (non-Hodgkin’s) lymphoma 2
* Costs from previous article publications were converted to Finnish purchasing po
standard deviation. IFX = infliximab. RTX = rituximab. ABA = abatacept. NS = not stthem could not be estimated using regression or any
other multivariate methods. As usual with skewed cost
distributions, the normal distribution assumption (com-
mon OLS) cut the distribution tails and the suitability of
GLM did not exceed the suitability of LN-OLS (see e.g.
Hallinen et al. 2006; Soini et al. 2012b).
These results were based on the list price (tariff ) infor-
mation obtained from the Finnish public hospitals. To
ascertain the coverage of the sample, we asked the prices
from the Finnish private hospitals and obtained none
(two said that they do not give such infusions). This was
an expected finding, because patient co-payments are
considerably higher in the private sector. In addition to
paying more for the administration of the IV-drug in
the private sector, the patients would also have to
pay the price of the drugs in full since the studied
IV-administered drugs are not covered by the Finnish
drug reimbursement system. Instead, in the publicly
funded hospitals the patient co-payment is a negligibly
small proportion of the total drug and drug administra-
tion costs (maximum 27.40 euros/visit). Due to this
characteristic of the Finnish multi-channelled health care
financing system, IV-drug infusions are not given by
(majority of) the private sector service providers.
These differences between drugs in terms of their ad-
ministration costs can be a result of multiple reasons and
the impact of most obvious one (number of infusions per
year) was shown. We controlled the hospital type and dos-
ing with multivariate methods. However, what was left
outside of the scope of this manuscript was the actual pri-
cing process (i.e. different providers may have different
systems to price their drug administration services), which
means that we assessed the unit costs for drug administra-
tion and health economic evaluation (technical and/or
allocative efficiency) was beyond the scope of this manu-
script. Obvious reasons for the differences in infusion ad-
ministration costs include resources (labour and materials
involved) and their use (productivity) as well as their unit
costs (more or less costly labour, buildings and equipment)
which are put together in the production process of ser-
vices that may or may not be efficient.ration costs (€2011)*








wer and reported in year 2011 value. N = number of observations. S.D. =
ated. a No administration costs for tocilizumab were found.
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(pharmaceuticals formulary) may have an impact to the
costs. Meanwhile the total costs per infusion are valid as
such, the administration costs per infusion are likely to
be too low in comparison to the true administration cost
invoiced from the municipalities due to the fact that
some hospitals and districts have power to negotiate
lower costs for their drug purchases (i.e. which results to
situation where we subtracted too much from the total
costs as the drug costs and results to lower than true ad-
ministration costs). Despite of this inaccuracy in the ana-
lysis, the administration costs obtained from the lists are
higher than the outpatient visit costs compared to the
Finnish average (Hujanen et al. 2008) or specific lists from
which the total and administration costs were analysed.
The presented pooled estimates describe the data and
apply for situations where drug, dosing and/or hospital
type are not taken into account. Using the stratification,
we aimed to present drug- and dose-specific costs for all
IV drugs, some of which may present with a low number
of list prices. With the statistical modelling of cost data,
we could adjust the differences (heterogeneity) in list
prices between the different IV drugs with enough list
prices and enable the statistical comparison of costs re-
lated to different IV drugs when they would be given in
equivalent settings.
Finding the optimal time to start biologic treatment
for RA patient is challenging especially when conven-
tional therapies evolve (e.g. Fautrel 2012) and the admin-
istration cost of intravenous biologic drug may depend,
for example, on the number of infusions received and
other patient characteristics which we could not take
into account in our analyses. In addition, there are five
noteworthy facts, which need to be taken into account
when interpreting and applying the results of this study.
The first and most important is the international com-
parability of costs. Although the relative Finnish health
care cost, measured as the proportion of gross-domestic
product consumed, to health care is low (around 9%),
the previous Finnish publications including the cost of
IV drug administration (Hallinen et al. 2010; Soini et al.
2011a) have used higher estimates compared with the
average estimates based on the publications. However, in
order to improve the international comparability, the main
results of this study can be converted to foreign values
using PPPs. The statistically adjusted (LN-OLS) mean ad-
ministration cost per IFX infusion for an adult (3 mg/kg)
is, for example, AU$476.17 / CA$375.62 / FR€264.89 / DE
€243.85 / JPY32,654.33 / RUB5501.69 / SEK2723.49 / UK
£201.40 / US$305.53 in Australia / Canada / France /
Germany / Japan / Russian Federation / Sweden / United
Kingdom / United States when converted to local pur-
chasing power and currency in 2011 using suitable PPP.
The respective mean administration costs per RTX 500–1000 mg infusion are AU$893.12 / CA$704.53 / FR€49
6.83 / DE€457.37 / JPY61,247.21 / RUB10,319.10 / SEK5
108.24 / UK£377.75 / US$573.06.
The second noteworthy fact is the perspective and
content of the cost estimate. In comparison with the
purchasing power adjusted and 2011 valued average
values obtained from the published RA literature (IFX
€193.92, RTX €172.00, ABA €158.75), our price list-
based stratified averages seem high (1.8–3.3 times). This
is not surprising since in many publications the cost of
IV drug administration is based on “outpatient visit as-
sumption” which may significantly underestimate the
cost due to, for example, ignorance of different infusion
times and severity of patient’s condition, the need for
monitoring the patient during and after infusion as well
as the potential need for hospital beds and associated
resources. Consequently, academic price lists may over-
look some cost items meanwhile they have to be in-
cluded in the local price lists in order to keep the
hospital working. This path leads to the perspective
discussion: the local price lists may reflect the ‘true’
opportunity cost (shadow price) of the service for the
payer – that is what the municipality is likely to lose in
terms of euros used for health care elsewhere when
some resident have a specific service (see e.g. Hallinen
et al. (2012); Soini (2008), for further discussion regard-
ing the opportunity costs).
In some countries home-based administration may be
done. However, home-based administration of IV bio-
logic RA drugs rarely done in Finland. These observa-
tions result to question, how comparable and credible is
the key assumption used in multiple evaluations (i.e.
outpatient visit costs between nations). For example, the
United Kingdom Personal Social Services Research Unit
(PSSRU) unit cost list (Curtis 2011) shows the cost of
£147 (€169.38; based on the average 1€ = £0.86788 dur-
ing the year 2011) for the outpatient visit in year 2011
which is significantly (2.9-times) less than e.g. adminis-
tration cost in the HTA submission (Woolacott et al.
2006, €484.57 in year 2011 value). Yet, the UK outpatient
visit cost is more in line with the Finnish (Hujanen et al.
2008) outpatient visit cost estimate (€202.29 in 2011
value). The outpatient visit tariffs in Finnish hospital price
lists are well in line with these estimates meanwhile the
cost for biologic drug infusion administration can be
higher. Unfortunately, unit cost list like Hujanen et al.
(2008) and Curtis 2011 are not available for many coun-
tries, including Sweden, and the detailing of the unit cost
lists and contents of the specific unit cost can vary consid-
erably between the nations.
The relatively high costs of IFX and RTX in this study
can be, for the minor part, explained by the fact that IFX
is used as a combination treatment with methotrexate
and RTX is used together with methylprednisolone
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relatively affordable), whereas ABA and TCZ can be
used as monotherapies or as combination therapies.
More obvious explanation is the infusion time, IFX and
RTX infusions take time. In the Finnish “official” price
list for health care resources (Hujanen et al. 2008), the
2011 valued unit cost estimate for a public internist or
oncologist outpatient visit (including tests) is €202.29 or
€227.14, respectively, which are in line with the results
of this study and have been used in the Finnish health
economic evaluations (e.g. Hallinen et al. 2010; Soini
et al. 2011). These outpatient visit costs are higher when
compared with the average values of published infusion
costs for RA or other diseases in the performed litera-
ture review and low compared with some of the
RA-related estimates obtained in this study. Thus, “out-
patient visit cost assumption” can underestimate the
costs of IV drug administration in RA.
The third fact is the analytical (costing) perspective.
The cost estimates in this study cover public health care
payer costs only (patient co-payments excluded, max-
imum €27.40/visit). The level of costs estimated using
the public health care price lists may be partly explained
by the fact that no data from Finnish private hospitals
were included in our data: in the Finnish official price
list (Hujanen et al. 2008), for example, the 2011-valued
unit cost for an outpatient visit to an internist was
€86.28 and to a rheumatologist €78.85 (including €9.29
payment for the receptionist office; excluding tests), and
for an oncologic I.V. infusion/injection taking less than
two hours was €135.17 (S.D. €215.30; payments for the
office excluded); all these private sector costs seem low
in comparison with the public sector costs.
On the other hand, our estimates do not cover all the
costs involved with IV drug administration. If we had tried
to analyse the costs from the direct health care cost per-
spective (regardless of the payer), the analysis should have
included patient co-payments (maximum €27.40/infusion)
and travelling costs. The societal perspective should have
also included the potential productivity losses.
The last fact is the applied indication. Based on the
performed literature review, the previously published
administration costs for RA differed from the adminis-
tration costs for Crohn’s disease, psoriatic arthritis,
ulcerative colitis or follicular lymphoma. However, the
differences were due to two studies (Bodger et al. 2009;
Woolacott et al. 2006) using a remarkably higher cost
estimate (€484.57 according to the 2011 value) for the
administration. To sum up, these facts may indicate that
the drug-specific estimates provided here for RA infu-
sion administration may be a “better than nothing” ap-
proximate estimate for diseases other than RA and
further studies should be done to find the most specific
unit costs for the health economic evaluations.In order to place the results of this study in a wider
context, the comparison of costs related to IV and other
types of drugs needs to be done with due caution. In the
case of drugs administered by health care personnel
(e.g. hospital-administered IV), adherences can be
known for certain. However, when the drug is taken at
home, for example, the secondary non-adherence is not
known (e.g. Hovstadius and Petersson 2011).
The results of our study suggest that there is uncertainty
related to drug infusion costs in previously published cost-
effectiveness studies. Therefore, our study highlights the
need for a more careful estimation of realistic administra-
tion costs for IV-drugs in health economic evaluations.
The international comparability of cost estimates and in-
cremental cost-effectiveness results could be improved by
using PPPs more frequently in the result reporting.
Conclusions
The infusion costs vary greatly between drugs. The fre-
quent assumption of administration costs equalling out-
patient visit cost can underestimate the true costs: the
average costs in this study were significantly higher than
those reported in the published literature.
Appendix 1. The list of the obtained price lists
Etelä-Karjalan sosiaali- ja terveyspiiri. Erikoissairaanhoi
don hinnasto 2011.
Etelä-Pohjanmaan sairaanhoitopiiri. Palveluhinnasto 2011.
Etelä-Savon sairaanhoitopiirin kuntayhtymä. Palvelu
hinnasto 1.1.2011. Available: http://www.esshp.fi/down
loader.asp?id=4852&type=1
Forssan seudun terveydenhuollon Ky. Hinnasto 2011.
Information received by e-mail 30th June 2011.
Helsingin ja Uudenmaan sairaanhoitopiiri. HUS palve
luhinnasto 2011, osa 2 suoriteperusteiset sairaanhoidol
liset palvelut.
Itä-Savon sairaanhoitopiirin kuntayhtymä Sosteri. Kun
talaskutuksen palveluhinnasto, erikoissairaanhoito, perus
terveydenhuolto, sosiaalipalvelut.
Kainuun maakunta-kuntayhtymän esh. Palveluhinnasto
2011. Information received by e-mail 30th June 2011.
Kanta-Hämeen sairaanhoitopiirin kuntayhtymä. Hin
nasto 2011.
Keski-Pohjanmaan erikoissairaanhoito- ja peruspalvelu
kuntayhtymä Kiuru. Palveluhinnasto 2011.
Keski-Suomen sairaanhoitopiiri. Hoitopalveluiden hin
nat 2011.
Lapin Sairaanhoitopiiri. Kuntalaskutuksen perusteena
olevat tulosyksiköt v. 2011. Information received by e-
mail 4th July 2011.
Länsi-Pohjan sairaanhoitopiirin kuntayhtymä. Polikli-
nikkakäyntien ja hoitopäivien hintaluokat kuntalaskutuk-
sessa 1.1.2011 lukien. Information received by e-mail 30th
June 2011.
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http://www.springerplus.com/content/2/1/531Pirkanmaan sairaanhoitopiiri. Tuotteet ja hinnat 2011,
1.5.2011 alkaen. Information received by e-mail 2nd
August 2011.
Pohjois-Karjalan sairaanhoito- ja sosiaalipalvelujen
kuntayhtymä. Tuotehinnasto 2011. Information received





Pohjois-Savon sairaanhoitopiiri. Kliinisten erikoisalojen
palvelutuotteet, suoritteet ja hinnat 2011.
Päijät-Hämeen sosiaali- ja terveyspalveluiden kuntay




Raahen aluesairaalan hinnat. Information received by
email 16th August 2011.
Satakunnan sairaanhoitopiiri. Palveluhinnasto 2011.
Available: http://www.satshp.fi/pls/wportal/url/ITEM/97
59642D26A39B32E0400A0A4B0027C4
Vaasan keskussairaala. Hinnasto 2011. Information re-
ceived by e-mail 30th June 2011.
Varkauden aluesairaalan hinnat. Information received
by e-mail 15th August 2011.
Varsinais-Suomen Sairaanhoitopiiri. TYKS Suoritehin
nasto 2011. Available: http://www.vsshp.fi/fi/dokumenti
t/28817/TYKS.pdf
Varsinais-Suomen sairaanhoitopiiri, Aluesairaalat. Suo
ritehinnasto 2011. Available: http://www.vsshp.fi/fi/doku
mentit/28042/Aluesairaalat.pdf
Varsinais-Suomen sairaanhoitopiiri, Turunmaan sairaa
la liikelaitos. Hinnat 2011. Available: http://www.vsshp.
fi/fi/dokumentit/26770/TMS.pdf
Varsinais-Suomen sairaanhoitopiiri. Hinnastolisäys 1–
2011, 2.3.2011. Available: http://www.vsshp.fi/fi/doku
mentit/27313/Lis%C3%A4ys%201-2011.pdf
Varsinais-Suomen sairaanhoitopiiri. Hinnastolisäys 2–
2011, 17.5.2011. Available: http://www.vsshp.fi/fi/doku
mentit/28545/Lis%C3%A4ys%202-2011.pdf
Ylä-Savon SOTE kuntayhtymä. Terveyden ja sairaan





95% CI: 95 per cent confidence interval; ABA: Abatacept; AIC: Akaike
information criteria; bDMARD: Biologic antirheumatic drug; BIC: Bayesian
information criteria; Coef.: Coefficient; GLM: Generalized linear modelling;
IFX: Infliximab; IV: Intravenous; kg: Kilogram; LL: Log likelihood; LN-
OLS: Ordinary least squares regression model with natural logarithm of
dependent variable; mg: Milligram; N: Number of observations; NR: Not
reported; NS: not stated; OECD: Organisation for economic cooperation and
development; OLS: Ordinary least squares; PPP: Purchasing power parity;R2: Coefficient of determination; RA: Rheumatoid arthritis; RTX: Rituximab;
S.D: Standard deviation; TCZ: Tocilizumab.
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